Latest Headlines

Latest Headlines

SEC: Provenge critic lied about her bets Dendreon stock would fall

Dendreon's lead treatment, prostate cancer vaccine Provenge, continues to post sales losses, leaving many pessimistic that the struggling biotech will be able to right the ship. Now, however, it appears one of the company's doubters may have had an ulterior motive.

For-sale Dendreon slashes 150 jobs, cuts more costs in hunker-down move

Dendreon's press releases have a definite broken-record sound. After posting another round of disappointing sales and earnings, the company is once again cutting jobs and costs. This time, it's 15% of the workforce, or about 150 jobs, and $125 million in spending.

Dendreon's for sale. Will anyone step up to battle for Provenge?

Just a few days ago, we learned that Dendreon is looking to woo a buyer. The question now is whether the struggling drugmaker can find a suitor to take on its baggage.

Suffering Dendreon puts itself on the block, Bloomberg says

Dendreon is getting tired of soldiering on alone. As  Bloomberg  reports, the Seattle-based company is casting about for buyers as its prostate cancer treatment Provenge continues to lag--and Dendreon's stock lags along with it.

With Lemtrada's EU nod, Sanofi preps for dual MS drug launches

Sanofi now has not one, but two, big multiple sclerosis launches to get under way in Europe. Two weeks after nabbing EU approval for its new MS pill Aubagio, Sanofi got regulatory clearance for Lemtrada.

Dendreon's Provenge sales off again, expected to miss for the year

Investors spanked the Seattle company severely in after-hours trading Thursday after it reported that sales of the drug were off 8% in the second quarter year-over-year to $73 million.

Dendreon's Provenge gets recommendation in Europe

Dendreon today got the best news it has had in a long time for its prostate cancer vaccine Provenge, a thumbs up from the Europe's Committee for Medicinal Products for Human Use (CHMP) for approval in Europe.

Dendreon's Provenge sales disappoint once again with 17% decline

Dendreon ($DNDN)  has posted another woeful set of quarterly numbers. The company's new efforts to pump up sales of its prostate cancer vaccine, Provenge, had little to show: Product revenue actually fell 18%, to $67.6 million.

SEC probes former Dendreon CEO's stock sales

The Securities and Exchange Commission's insider trading team has Dendreon under a microscope. The agency has launched a civil investigation into stock trades by former CEO Mitchell Gold to see whether he acted on inside information about disappointing Provenge sales.

Boy, was I wrong about Dendreon, analyst says

It isn't often that a Wall Street analyst admits to a mistake.